RAMM Pharma (XCNQ:RAMM) Operating Income: C$-3.99 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is RAMM Pharma Operating Income?

RAMM Pharma XCNQ:RAMM +100.00% Operating Income is C$-3.99 Mil as of Apr. 2026. The stock has 4 warning signs investors should review.

RAMM Pharma's Operating Income for the three months ended in Apr. 2026 was C$-0.82 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Apr. 2026 was C$-3.99 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. RAMM Pharma's Operating Income for the three months ended in Apr. 2026 was C$-0.82 Mil. RAMM Pharma's Revenue for the three months ended in Apr. 2026 was C$0.19 Mil. Therefore, RAMM Pharma's Operating Margin % for the quarter that ended in Apr. 2026 was -433.68%.

Good Sign:

RAMM Pharma Corp operating margin is expanding. Margin expansion is usually a good sign.

RAMM Pharma's 5-Year average Growth Rate for Operating Margin % was 2.60% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. RAMM Pharma's annualized ROC % for the quarter that ended in Apr. 2026 was -54.79%. RAMM Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was -18.53%.

RAMM Pharma  (XCNQ:RAMM) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

RAMM Pharma's annualized ROC % for the quarter that ended in Apr. 2026 is calculated as:

ROC % (Q: Apr. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2026 ) + Invested Capital (Q: Apr. 2026 ))/ count )
=-3.296 * ( 1 - 0% )/( (6.176 + 5.855)/ 2 )
=-3.296/6.0155
=-54.79 %

where

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.45 - 3.496 - ( 0.985 - max(0, 3.558 - 2.336+0.985))
=6.176

Invested Capital(Q: Apr. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7.127 - 2.737 - ( 0.12 - max(0, 2.781 - 1.316+0.12))
=5.855

Note: The Operating Income data used here is four times the quarterly (Apr. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

RAMM Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Apr. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2026  Q: Apr. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.104/( ( (6.111 + max(-2.487, 0)) + (5.808 + max(-1.905, 0)) )/ 2 )
=-1.104/( ( 6.111 + 5.808 )/ 2 )
=-1.104/5.9595
=-18.53 %

where Working Capital is:

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.112 + 0.876 + 0.022) - (3.496 + 0 + 0.00099999999999989)
=-2.487

Working Capital(Q: Apr. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.082 + 0.731 + 0.019) - (2.737 + 0 + 0)
=-1.905

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

RAMM Pharma's Operating Margin % for the quarter that ended in Apr. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Apr. 2026 )/Revenue (Q: Apr. 2026 )
=-0.824/0.19
=-433.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

RAMM Pharma Operating Income Related Terms

RAMM Pharma Operating Income Historical Data

* Premium members only.

The historical data trend for RAMM Pharma's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RAMM Pharma Operating Income Chart

RAMM Pharma Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Operating Income
Get a 7-Day Free Trial -6.64 -7.93 -7.07 -6.75 -4.29

RAMM Pharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 -0.95 -1.29 -0.93 -0.82

RAMM Pharma Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of C$-3.99 Mil mean?
RAMM Pharma (XCNQ:RAMM) has a Operating Income of C$-3.99 Mil as of Apr. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on RAMM Pharma and its competitors.
Is RAMM Pharma's Operating Income too high?
RAMM Pharma's current Operating Income is C$-3.99 Mil.
How does RAMM Pharma's Operating Income compare to ZTS and UTHR?
RAMM Pharma's Operating Income of C$-3.99 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on RAMM Pharma and its competitors. RAMM Pharma's current Operating Income is C$-3.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RAMM Pharma stock overvalued right now?
Based on GuruFocus' analysis, RAMM Pharma (XCNQ:RAMM) is currently considered Fairly Valued. The stock's GF Value™ is C$0.01, compared to a current price of C$0.01 — trading right at its estimated fair value. The current Operating Income is C$-3.99 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For RAMM Pharma (XCNQ:RAMM), the current Operating Income is C$-3.99 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RAMM Pharma Business Description

Address 82 Richmond Street E, Toronto, ON, CAN, M5C 1P1
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.